Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | HTR5A | P47898 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376094 | 1.00 | TRPV1 (0.43) | TRPV1TRPM8HDAC1NOS3NOS1 | |
| SCHEMBL2374727 | 0.87 | HTR5A (0.41) | HDAC1NOS3NOS1NOS2HTR5A | |
| SCHEMBL2374728 | 0.87 | HTR5A (0.41) | HDAC1NOS3NOS1NOS2HTR5A | |
| SCHEMBL2375592 | 0.80 | NOS3 (0.44) | TRPV1TRPM8HDAC1NOS3NOS1 | |
| SCHEMBL2375583 | 0.80 | NOS3 (0.44) | TRPV1TRPM8HDAC1NOS3NOS1 | |
| SCHEMBL2375587 | 0.80 | NOS3 (0.44) | TRPV1TRPM8HDAC1NOS3NOS1 | |
| SCHEMBL2374579 | 0.79 | NOS3 (0.43) | TRPV1TRPM8HDAC1NOS3NOS1 | |
| SCHEMBL2374585 | 0.79 | NOS3 (0.43) | TRPV1TRPM8HDAC1NOS3NOS1 | |
| SCHEMBL2374575 | 0.79 | NOS3 (0.43) | TRPV1TRPM8HDAC1NOS3NOS1 | |
| SCHEMBL1124433 | 0.78 | NOS3 (0.51) | TRPV1TRPM8NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | TRPV1 2628/4885TRPM8 2184/4885HDAC1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.